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Abstract
Background—Understanding of cancer outcomes is limited by data fragmentation. We analyzed 
the information yielded by integrating breast cancer data from three sources: electronic medical 
records (EMRs) of two healthcare systems and the state registry.
Methods—We extracted diagnostic test and treatment data from EMRs of all breast cancer 
patients treated from 2000–2010 in two independent California institutions: a community-based 
practice (Palo Alto Medical Foundation) and an academic medical center (Stanford University). 
We incorporated records from the population-based California Cancer Registry (CCR), and then 
linked EMR-CCR datasets of Community and University patients.
Results—We initially identified 8210 University patients and 5770 Community patients; linked 
datasets revealed a 16% patient overlap, yielding 12,109 unique patients. The proportion of all 
Community patients, but not University patients, treated at both institutions increased with 
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worsening cancer prognostic factors. Before linking datasets, Community patients appeared to 
receive less intervention than University patients (mastectomy: 37.6% versus 43.2%; 
chemotherapy: 35% versus 41.7%; magnetic resonance imaging (MRI): 10% versus 29.3%; 
genetic testing: 2.5% versus 9.2%). Linked Community and University datasets revealed that 
patients treated at both institutions received substantially more intervention (mastectomy: 55.8%; 
chemotherapy: 47.2%; MRI: 38.9%; genetic testing: 10.9%; p<0.001 for each three-way 
institutional comparison).
Conclusion—Data linkage identified 16% of patients who were treated in two healthcare 
systems and who, despite comparable prognostic factors, received far more intensive treatment 
than others. By integrating complementary data from EMRs and population-based registries, we 
obtained a more comprehensive understanding of breast cancer care and factors that drive 
treatment utilization.
Keywords
Breast cancer; electronic medical records; bioinformatics; SEER registry; data linkage; outcomes 
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INTRODUCTION
Advances in breast cancer diagnosis and treatment1–4 offer many effective options, and raise 
questions about the comparative effectiveness of different care pathways.5–7 National 
initiatives prioritize comparing the effectiveness of treatments in diverse practice 
settings,8–10 requiring demographic and long-term follow-up data from their 
populations.11–13 Studies of real-world cancer outcomes, outside of clinical trials, have been 
limited by the fragmentation and lack of detail in available data. Population-based registries 
such as the Surveillance, Epidemiology and End Results (SEER) program excel at tracking 
demographics and incidence, but lack essential details about treatments and diagnostic 
tests.14, 15 Institutional electronic medical records (EMR) contain extensive treatment 
information; however, they are subject to a measurement bias of unknown magnitude, 
namely the under-reporting of care delivered outside the institution and its outcomes.
Linking EMR-derived data across healthcare systems offers the promise of more complete 
information, but the challenge of disagreement between institutions, which may require 
laborious review of patients’ charts for resolution. We linked data from the EMRs of an 
academic medical center and a multi-site community practice in the same catchment region. 
To provide a gold-standard for patient identification and treatment summaries, we also 
linked to the statewide population-based California Cancer Registry (CCR, a SEER 
component).16 Our hypothesis was that this three-way data linkage would offer a practical 
and scalable approach to identifying patients treated in more than one healthcare system, and 
would provide information about variability in cancer care which could not be obtained 
otherwise.
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METHODS
Data Resource Environment
Our project (Oncoshare) began in 2009 to integrate data from EMRs of Stanford University 
Hospital (SU) and Palo Alto Medical Foundation (PAMF). SU is an academic medical 
center; PAMF is a multi-site community practice in Alameda, San Mateo, Santa Clara and 
Santa Cruz counties, California. SU (University) is within one mile of the nearest PAMF 
(Community) site. Community patients have health maintenance organization (HMO) and 
fee-for-service insurance; University patients have various insurance plans, including 
Medicaid. Although inpatient care provided by Community physicians sometimes occurs in 
University facilities, the institutions are legally and financially separate, with non-
overlapping staff. All research was approved by University and Community Institutional 
Review Boards (IRB) and the State of California IRB (for use of CCR data).
Clinical Data Extraction
We extracted data from University and Community EMRs (Epic, Verona, WI) and from a 
University warehouse for clinical data collected before Epic implementation in 2007. All 
University clinical systems data since the mid-1990s reside in the Stanford Translational 
Research Integrated Database Environment (STRIDE), a warehouse and integration 
platform for research data extraction and analysis.17 Real-time electronic data feeds supply 
clinical information to STRIDE via HL7 technology; extract, transform and load processes 
out of Epic and into STRIDE occur daily. STRIDE contains one terabyte of data in the form 
of transcribed dictations and physicians’ text notes, billing codes, laboratory and pharmacy 
orders, medication and radiotherapy administration records, laboratory results, radiology and 
pathology reports. University chemotherapy data are available from the Epic Beacon 
provider order entry system since 2008. Community clinical data are housed in three EMR 
systems: Epic for everything except chemotherapy orders, IDX for billing information, and 
IntelliDose, an ancillary computer system dedicated to chemotherapy and used since 2000. 
To ensure uniform coding, chemotherapy data elements in each EMR were mapped to 
RxNorm,18 a standardized drug lexicon, and diagnostic test data elements were mapped to 
National Cancer Institute codes.19 We identified clinically important interventions, 
including surgery, chemotherapy, radiation, and emerging diagnostic tests: breast magnetic 
resonance imaging (MRI), positron emission tomography (PET), and genetic testing for 
BRCA1 and BRCA2 (BRCA1/2) mutations. We excluded interventions occurring more than 
90 days before cancer diagnosis.
CCR Data Addition
We requested CCR records, with all data fields including age, race/ethnicity, tumor stage, 
grade, histology, receptors [estrogen receptor (ER), progesterone receptor (PR) and HER2]; 
and treatment summaries (comprising reports from any California institution of receiving 
surgery, chemotherapy, and/or radiation) for all breast cancer patients treated at University 
and/or Community facilities from 2000–2010. Census block groups were geocoded based on 
patients’ residential addresses at the time of diagnoses. The 3% of cases whose address 
could not be precisely geocoded were assigned to a census block group within their county 
of residence. We assigned neighborhood socioeconomic status (SES) using a previously 
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developed and widely used index that incorporates 2000 United States Census data on 
education, income, occupation and housing costs, based on selection via principal 
components analysis.20 We categorized this measure by quintiles based on the distribution 
of the composite SES index across California. CCR and EMR records were linked using 
names, social security numbers, medical record numbers and birthdates. All personal 
identifying information was removed, and clinical encounter dates randomly offset by 30 
days, before research use of the data.21
Patient Cohort Identification
We defined cohorts representing all patients treated for breast cancer at Community and/or 
University facilities from January 1, 2000 through January 1, 2010. Eligible patients were 
female, ≥18 years old, and met at least one of the following criteria within the period: 1) the 
CCR reported a breast cancer diagnosis and/or treatment at Community and/or University 
facilities; 2) University and/or Community billing records included a diagnostic code for 
breast cancer or ductal carcinoma in situ [International Classification of Diseases-9 (ICD-9) 
codes 174.9 or 233.0], billed by a breast cancer specialist (defined as a surgeon, medical 
oncologist or radiation oncologist). Treating institution was based on clinician affiliation, 
not location; a Community surgeon operating at the University was coded as Community. 
Institution was determined first by EMR-based billing records: patients who had University 
records of breast cancer-specific interventions (surgery, chemotherapy, radiation) were 
coded as University, and likewise for Community, as confirmed by the CCR. For patients 
lacking treatment records, institution was defined by billing records for cancer-related 
diagnostic tests including PET and genetic testing, and if there were no such records, by 
presence in University or Community internal tumor registries, which report to the CCR. 
MRI was not used to determine treating institution because before 2006 some Community 
patients visited the University for MRI only. After generating separate University and 
Community cohorts (defined hereafter as “EMR-CCR cohorts”), we linked these two EMR-
CCR cohorts to identify patients treated at both institutions.
Quality Assurance and Analytical Cohort Development
We validated and applied an algorithm to link records across data sources.21, 22 To ensure 
subjects’ eligibility, we developed analytical cohorts, from which we excluded patients 
lacking data on all of the following (considered essential for analyzing breast cancer care): 
stage, tumor receptors (ER, PR, HER2), and any diagnostic or treatment intervention. We 
applied more stringent inclusion criteria for patients identified in EMRs only but not in the 
CCR, because review of physicians’ notes and pathology reports in EMRs revealed that 
many such patients had received breast cancer ICD-9 codes erroneously, often coincident 
with prophylactic mastectomy or tamoxifen used for breast cancer risk reduction. These 
stringent inclusion criteria were cancer-specific pathology data (stage and/or tumor 
receptors) and treatments (chemotherapy and/or radiation). This algorithm was applied 
within each institution before linking EMR-CCR cohorts, and to the overall cohort after 
linkage.
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Statistical Analysis
Patient characteristics, receipt of treatments and diagnostic tests were tabulated before and 
after linkage of University and Community EMR-CCR cohorts. After linkage, measures for 
patients treated at University, Community, and both institutions were compared using the 
Chi-squared statistic. All p values were two-sided.
RESULTS
Analytical Cohorts
We identified a maximally inclusive University cohort of 8892 patients. Applying our 
eligibility criteria left 8210 patients (92.3%) in the University analytical cohort. Repeating 
these steps, we identified a maximally inclusive Community cohort of 6304 patients, and 
retained 5770 (91.5%) in the Community analytical cohort; adding these cohorts produced 
an apparent total of 13,980 patients. Linked records from the University and Community 
EMR-CCR cohorts yielded a maximally inclusive cohort of 13,238 unique patients, of 
whom we retained 12,109 (91.5%) in the Combined analytical cohort (Figure 1a–c).
Patient Characteristics, Before and After EMR-CCR Cohort Linkage
Before linking University and Community EMR-CCR cohorts, University patients appeared 
younger, with lower SES and worse cancer prognostic factors than Community patients 
(Table 1). Linked EMR-CCR cohorts identified a third group of patients who were treated at 
both institutions (defined hereafter as “Both”). “Both” patients were significantly more 
likely to be Asian (University-only 14%, Community-only 13.9%, “Both” 17.2%) and of 
highest-quintile SES (University-only 49.2%, Community-only 64.6%, “Both” 75.2%). 
“Both” patients had intermediate prognostic factors, including age (<40 years: University-
only 10.9%, Community-only 3.7%, “Both” 10%), stage (III or IV: University-only 13.6%, 
Community-only 6.8%, “Both” 10.2%), tumor receptor subtype (for the poor prognosis 
subtypes,23 HER2-positive or ER-, PR- and HER2-negative: University-only 29.1%, 
Community-only 14.5%, “Both” 25.9%), and grade (3: University-only 32.3%, Community-
only 19.8%, “Both” 29.5%; p<0.001 for each reported three-way comparison). As 
prognostic factors worsened, including decreasing age, increasing stage, increasing grade, 
and less favorable receptor subtype,24–26 an increasing proportion of Community patients 
(but not University patients) fell into the “Both” category.
Treatments and Diagnostic Tests, Before and After EMR-CCR Cohort Linkage
Treatment information was most often available from the CCR, but diagnostic test 
information was available only from EMRs, through providers’ notes and billing (Table 2). 
For example, CCR data identified about 95% of all women with evidence from any source 
of having received mastectomy, but institution-specific data identified only 25–50% of these 
cases. For women in the “Both” category, the “institution-specific” data performed better, 
reflecting a greater yield from combining EMR-derived data from two institutions. For 
chemotherapy, Community billing data offered somewhat more complete case finding than 
that from the University. Linked University and Community EMR-CCR cohorts revealed 
that the usage of all interventions was highest among the “Both” patients. For example, 
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mastectomy utilization was as follows: University-only 39.7%, Community-only 30.5%, 
“Both” 55.8%, and similarly for bilateral mastectomy: University-only 8%, Community-
only 5.2%, “Both” 13.2%. Figure 2 illustrates another example: the differential use of MRI 
among University-only (32.9%), Community-only (32.8%), and “Both” (66%) patients by 
2009 (p<0.001 for each three-way comparison).
DISCUSSION
To study breast cancer care beyond the walls of a single institution, we linked state registry 
records to data extracted from the EMRs of two healthcare systems, one community-based 
and one university-affiliated. This three-way data linkage generated unique insights. We 
found a 16% patient overlap between nearby healthcare systems, which enables an estimate 
of the magnitude of missing treatment information in single-institution studies. We 
discovered a striking care pattern, with Community patients increasingly likely to be treated 
at both institutions as cancer prognosis worsened, and with “Both” patients receiving the 
most intensive intervention despite having intermediate cancer prognostic factors. These 
findings illustrate how efforts to compare outcomes across real-world settings must account 
for measured and unmeasured risk factors and patient preferences.
Previous studies have integrated complementary databases, supplementing SEER-derived 
data with treatment details from Medicare claims27, 28 and HMOs.29, 30 This study’s novelty 
lies in linking data from the EMRs of nearby yet independent healthcare systems, anchored 
by data from the CCR, a SEER component. We assessed data quality by reviewing several 
hundred de-identified patient records, and evaluating agreement between all sources; rare 
conflicts were adjudicated by physician review.21, 22 The three-way linkage identified the 
most informative source for each variable, with the CCR most informative about treatment 
utilization, and EMRs the only source of diagnostic test data. Missing data were reduced by 
the three-way linkage, with “Both” patients having the most data available.
We encountered limitations in extracting research data from EMRs. We extracted structured 
data from billing, drug ordering and administration records, and performed simple natural 
language processing of diagnostic reports, but many important concepts remain buried in the 
unstructured paragraphs of clinicians’ notes. These include nuances of decision-making 
which lack representation elsewhere, notably physicians’ recommendations and patients’ 
preferences. EMRs also promise a wealth of clinical detail that cannot be obtained from 
administrative databases or registries, including the images and reports of radiologic exams 
and genomic sequencing tests. Some of this information can be extracted and encoded as 
discrete data elements (for example, BI-RADS scores for mammogram and breast MRI), 
whereas identifying the determinants of treatment choices may require advances in natural 
language processing. The accurate retrieval of such specific patient information from 
unstructured, free-text EMR notes remains an active area of research.31, 32 Given the EMR’s 
unique potential to enhance understanding of cancer outcomes, studies to optimize the 
clinical and research uses of EMRs should remain a high priority.33, 34 Some limitations 
may be addressed through EMR changes, with structured fields facilitating data extraction; 
others require new data sources, including patient-reported information.8, 35 Bridging such 
gaps should be a priority of emerging data integration initiatives.36, 37 Health information 
Kurian et al. Page 6
Cancer. Author manuscript; available in PMC 2015 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
technology is developing rapidly, and the decade of 2000–2010 witnessed the 
implementation of EMRs and complementary databases. EMR modules for clinical data 
exchange between University and Community (Care Everywhere: Epic, Verona WI) and 
between patients and physicians (Patient Portal: Epic, Verona WI) were activated in 2012, 
and should enhance both clinical care and research. In the future, standardized data 
representation models will facilitate the interoperability of digital health data between 
institutions.
The “Both” patients offer an intriguing glimpse across healthcare systems. This category 
comprised 16% of patients, disproportionately representing top-quintile SES and 
intermediate cancer prognostic factors. Without information about physician referrals and 
patient preferences, we do not know why patients accessed both systems, but the over-
representation of sicker Community patients in the “Both” category suggests tertiary center 
consultation on challenging cases. The “Both” patients are remarkable for their significantly 
greater utilization of every intervention studied, including mastectomy, chemotherapy, 
radiation, MRI, PET, and genetic testing. One explanation might be that “University-only” 
and “Community-only” patients actually accessed other healthcare systems, leading us to 
underestimate their test use; however, such potential under-ascertainment cannot explain 
treatment differences recorded in the CCR, which aggregates statewide cancer data 
comprehensively because of mandated reporting. Previous studies reported rising 
mastectomy rates,38–42 despite a lack of survival benefit,4, 43, 44 and found correlations with 
an increase in diagnostic testing.39, 45, 46 The “Both” patients’ high SES might explain their 
greater use of interventions which are usually optional, such as MRI and bilateral 
mastectomy,25, 47–50 but we lack information about other factors that may drive utilization, 
including family cancer history and clinical trial participation. Assessing the value added by 
specific interventions51–53 will require a deeper understanding of the patient, physician and 
healthcare factors that shape the care patterns we observed.
Integrating breast cancer data from two EMRs and the state registry proved feasible and 
informative, broadening our understanding of care beyond what could be achieved from just 
one or two data sources. This approach offers insight about real-world treatment across 
healthcare systems, which can advance comparative effectiveness and outcomes research in 
oncology.
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Figure 1. 
Patient identification and inclusion in analytical cohorts for a) University, b) Community, 
and c) University and Community combined.
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Figure 2. 
Use of breast magnetic resonance imaging by year and treating institution: University, 
Community, and Both.
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